Agios Pharmaceuticals Inc AGIO:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/28/24 EDT
29.24UNCH (UNCH)
Volume
31,134
Close
29.24UNCH (UNCH)
Volume
403,651
52 week range
19.80 - 35.50
Loading...
  • Open29.19
  • Day High29.42
  • Day Low28.82
  • Prev Close29.12
  • 52 Week High35.50
  • 52 Week High Date02/27/24
  • 52 Week Low19.80
  • 52 Week Low Date10/27/23

Key Stats

  • Market Cap1.643B
  • Shares Out56.19M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta0.83
  • YTD % Change31.3

KEY STATS

  • Open29.19
  • Day High29.42
  • Day Low28.82
  • Prev Close29.12
  • 52 Week High35.50
  • 52 Week High Date02/27/24
  • 52 Week Low19.80
  • 52 Week Low Date10/27/23
  • Market Cap1.643B
  • Shares Out56.19M
  • 10 Day Average Volume0.64M
  • Dividend-
  • Dividend Yield-
  • Beta0.83
  • YTD % Change31.3

RATIOS/PROFITABILITY

  • EPS (TTM)-6.33
  • P/E (TTM)-4.62
  • Fwd P/E (NTM)-5.00
  • EBITDA (TTM)-384.864M
  • ROE (TTM)-36.83%
  • Revenue (TTM)26.823M
  • Gross Margin (TTM)89.26%
  • Net Margin (TTM)-1,312.64%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date05/02/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Agios Pharmaceuticals Inc

 

Profile

MORE
Agios Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and delivering transformative therapies for patients living with rare diseases. It markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its genetically defined disease (GDD) portfolio, PYRUKYND (Mitapivat), is an activator of both wild-type and a...
Jacqualyn Fouse Ph.D.
Chairman of the Board
Brian Goff
Chief Executive Officer, Director
Cecilia Jones
Chief Financial Officer
Address
88 Sidney Street
Cambridge, MA
02139
United States

Top Peers

SYMBOLLASTCHG%CHG
FDMT
4D Molecular Therapeutics Inc
31.86UNCHUNCH
AKRO
Akero Therapeutics Inc
25.26UNCHUNCH
MORF
Morphic Holding Inc
35.20UNCHUNCH
INBX
Inhibrx Inc
34.96UNCHUNCH
KURA
Kura Oncology Inc
21.33UNCHUNCH